Late-Onset Severe Chronic Active EBV in a Patient for Five Years with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1)

JI Cohen, JE Niemela, JL Stoddard, S Pittaluga… - Journal of clinical …, 2015 - Springer
JI Cohen, JE Niemela, JL Stoddard, S Pittaluga, H Heslop, ES Jaffe, K Dowdell
Journal of clinical immunology, 2015Springer
Abstract Severe chronic active Epstein-Barr virus (CAEBV) disease is defined as a severe
progressive illness lasting 6 months or longer with infiltration of tissues with EBV-positive
lymphocytes, markedly elevated levels of EBV DNA in the blood, and no known
immunodeficiency such as HIV. These patients usually have fever, splenomegaly,
lymphadenopathy, and may have markedly elevated EBV antibody titers to viral capsid
antigen. Although the cause of most cases of severe CAEBV is unknown, one well …
Abstract
Severe chronic active Epstein-Barr virus (CAEBV) disease is defined as a severe progressive illness lasting 6 months or longer with infiltration of tissues with EBV-positive lymphocytes, markedly elevated levels of EBV DNA in the blood, and no known immunodeficiency such as HIV. These patients usually have fever, splenomegaly, lymphadenopathy, and may have markedly elevated EBV antibody titers to viral capsid antigen. Although the cause of most cases of severe CAEBV is unknown, one well-documented case was associated with compound heterozygous mutations in PRF1 (perforin 1). Here we report a patient with prolonged severe CAEBV who underwent bone marrow transplant for his disease and subsequently was found to have compound heterozygous mutations in STXBP2 (MUNC18-2) as well as a heterozygous mutation in PRF1 (perforin 1).
Springer